MTOR and cancer: The phosphoinositide-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is commonly activated in cancer by several mechanism including activating mutations of PIK3CA or AKT1 and or loss of phosphatase and tensin homolog (PTEN) [1] .